Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy

Donovan Watza^{1

2}, Kristen S Purrington^{1

2}, Kang Chen^{1

2

3}, Ann G Schwartz^{1

2}

Affiliations

¹ Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
² Karmanos Cancer Institute, Detroit, MI, USA.
³ Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA.

Editorial

Donovan Watza et al. J Thorac Dis. 2017 Nov.

. 2017 Nov;9(11):4162-4164.

doi: 10.21037/jtd.2017.10.35.

Donovan Watza^{1

2}, Kristen S Purrington^{1

2}, Kang Chen^{1

2

3}, Ann G Schwartz^{1

2}

¹ Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
² Karmanos Cancer Institute, Detroit, MI, USA.
³ Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.
Ganesan AP, Clarke J, Wood O, Garrido-Martin EM, Chee SJ, Mellows T, Samaniego-Castruita D, Singh D, Seumois G, Alzetani A, Woo E, Friedmann PS, King EV, Thomas GJ, Sanchez-Elsner T, Vijayanand P, Ottensmeier CH. Ganesan AP, et al. Nat Immunol. 2017 Aug;18(8):940-950. doi: 10.1038/ni.3775. Epub 2017 Jun 19. Nat Immunol. 2017. PMID: 28628092 Free PMC article.

1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed
1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
1. Carbone DP, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 2017;376:2415-26. 10.1056/NEJMoa1613493 - DOI - PMC - PubMed
1. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509-20. 10.1056/NEJMoa1500596 - DOI - PMC - PubMed
1. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 2015;348:124-8. 10.1126/science.aaa1348 - DOI - PMC - PubMed